<!DOCTYPE html>
<html >

<head>

  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <title>Conferences 2016</title>
  <meta content="text/html; charset=UTF-8" http-equiv="Content-Type">
  <meta name="description" content="A guide to authoring books with R Markdown, including how to generate figures and tables, and insert cross-references, citations, HTML widgets, and Shiny apps in R Markdown. The book can be exported to HTML, PDF, and e-books (e.g. EPUB). The book style is customizable. You can easily write and preview the book in RStudio IDE or other editors, and host the book wherever you want (e.g. bookdown.org).">
  <meta name="generator" content="bookdown 0.0.79 and GitBook 2.6.7">

  <meta property="og:title" content="Conferences 2016" />
  <meta property="og:type" content="book" />
  <meta property="og:url" content="http://shanmdphd.github.io/Conferences/" />
  <meta property="og:image" content="http://shanmdphd.github.io/Conferences/images/cover.png" />
  <meta property="og:description" content="A guide to authoring books with R Markdown, including how to generate figures and tables, and insert cross-references, citations, HTML widgets, and Shiny apps in R Markdown. The book can be exported to HTML, PDF, and e-books (e.g. EPUB). The book style is customizable. You can easily write and preview the book in RStudio IDE or other editors, and host the book wherever you want (e.g. bookdown.org)." />
  <meta name="github-repo" content="shanmdphd/PAPER" />

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="Conferences 2016" />
  
  <meta name="twitter:description" content="A guide to authoring books with R Markdown, including how to generate figures and tables, and insert cross-references, citations, HTML widgets, and Shiny apps in R Markdown. The book can be exported to HTML, PDF, and e-books (e.g. EPUB). The book style is customizable. You can easily write and preview the book in RStudio IDE or other editors, and host the book wherever you want (e.g. bookdown.org)." />
  <meta name="twitter:image" content="http://shanmdphd.github.io/Conferences/images/cover.png" />

<meta name="author" content="Sungpil Han">

<meta name="date" content="2016-07-14">

<script type="text/x-mathjax-config">
MathJax.Hub.Config({
  TeX: { equationNumbers: { autoNumber: "AMS" } }
});
</script>

  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta name="apple-mobile-web-app-capable" content="yes">
  <meta name="apple-mobile-web-app-status-bar-style" content="black">
  
  
<link rel="prev" href="observational-study.html">
<link rel="next" href="diagnostic-test-biomarker-study.html">

<script src="libs/jquery/jquery.min.js"></script>
<link href="libs/gitbook/css/style.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook/css/plugin-fontsettings.css" rel="stylesheet" />










<link rel="stylesheet" href="css/style.css" type="text/css" />
</head>

<body>


  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li><a href="./">Conferences</a></li>

<li class="divider"></li>
<li class="chapter" data-level="1" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i><b>1</b> Introduction</a></li>
<li class="chapter" data-level="2" data-path="kscpt.html"><a href="kscpt.html"><i class="fa fa-check"></i><b>2</b> 2016 KSCPT</a><ul>
<li class="chapter" data-level="2.1" data-path="opening-remark.html"><a href="opening-remark.html"><i class="fa fa-check"></i><b>2.1</b> Opening Remark</a></li>
<li class="chapter" data-level="2.2" data-path="first-session.html"><a href="first-session.html"><i class="fa fa-check"></i><b>2.2</b> First Session</a><ul>
<li class="chapter" data-level="2.2.1" data-path="first-session.html"><a href="first-session.html#precision-medicine-a-clinical-pharmacological-perspective"><i class="fa fa-check"></i><b>2.2.1</b> 13:20~14:00 Precision Medicine: A Clinical Pharmacological Perspective</a></li>
<li class="chapter" data-level="2.2.2" data-path="first-session.html"><a href="first-session.html#the-role-of-pharmacogenomics-in-drug-development-regulatory-review-and-clinical-practice"><i class="fa fa-check"></i><b>2.2.2</b> 14:00~14:30 The role of pharmacogenomics in drug development, regulatory review and clinical practice</a></li>
<li class="chapter" data-level="2.2.3" data-path="first-session.html"><a href="first-session.html#the-liver-gut-microbiota-axis-modulates-inter-individual-variability-in-xenobiotic-disposition-and-toxicology"><i class="fa fa-check"></i><b>2.2.3</b> 14:30~15:00 The Liver-Gut Microbiota Axis Modulates Inter-Individual Variability in Xenobiotic Disposition and Toxicology</a></li>
</ul></li>
<li class="chapter" data-level="2.3" data-path="second-session.html"><a href="second-session.html"><i class="fa fa-check"></i><b>2.3</b> Second Session</a><ul>
<li class="chapter" data-level="2.3.1" data-path="second-session.html"><a href="second-session.html#the-role-of-stem-cells-in-discovery-and-validation-of-pharmacogenomic-markers"><i class="fa fa-check"></i><b>2.3.1</b> 15:20~15:50 The role of stem cells in discovery and validation of pharmacogenomic markers</a></li>
<li class="chapter" data-level="2.3.2" data-path="second-session.html"><a href="second-session.html#pharmacogenomics-and-epigenomics"><i class="fa fa-check"></i><b>2.3.2</b> 15:50~16:20 Pharmacogenomics and Epigenomics</a></li>
<li class="chapter" data-level="2.3.3" data-path="second-session.html"><a href="second-session.html#emerging-roles-of-human-cyp1b1-in-cancer-growth-and-metastasis"><i class="fa fa-check"></i><b>2.3.3</b> 16:20~16:50 Emerging roles of human CYP1B1 in cancer growth and metastasis</a></li>
<li class="chapter" data-level="2.3.4" data-path="second-session.html"><a href="second-session.html#omics-for-precision-medicine-clinical-implementation-in-oncology"><i class="fa fa-check"></i><b>2.3.4</b> 16:50~17:20 omics for precision Medicine : Clinical Implementation in oncology</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="3" data-path="translation-and-convergence-for-future-medicine.html"><a href="translation-and-convergence-for-future-medicine.html"><i class="fa fa-check"></i><b>3</b> “Translation and Convergence for Future Medicine”</a><ul>
<li class="chapter" data-level="3.1" data-path="plenary-session-ii-rd-.html"><a href="plenary-session-ii-rd-.html"><i class="fa fa-check"></i><b>3.1</b> Plenary Session II “의료기술및 R&amp;D 변화의최신동향”</a><ul>
<li class="chapter" data-level="3.1.1" data-path="plenary-session-ii-rd-.html"><a href="plenary-session-ii-rd-.html#lecture-1--------"><i class="fa fa-check"></i><b>3.1.1</b> 13:30 ~ 14:15 Lecture 1 :의료분야에서의 빅데이터 :임상연구 및 진료를 위한 애널리틱스의 활용</a></li>
<li class="chapter" data-level="3.1.2" data-path="plenary-session-ii-rd-.html"><a href="plenary-session-ii-rd-.html#lecture-2----"><i class="fa fa-check"></i><b>3.1.2</b> 14:15 ~ 15:00 Lecture 2 :합성 항체에서 합성 단백질로</a></li>
</ul></li>
<li class="chapter" data-level="3.2" data-path="parallel-session-i-chairperson-.html"><a href="parallel-session-i-chairperson-.html"><i class="fa fa-check"></i><b>3.2</b> Parallel Session I “의료분야에서의빅데이터” Chairperson :김태원(서울아산병원임상의학연구소장) [대강당]</a><ul>
<li class="chapter" data-level="3.2.1" data-path="parallel-session-i-chairperson-.html"><a href="parallel-session-i-chairperson-.html#lecture-1------alexander-turchin-harvard-university-brigham-and-womens-hospital-usa"><i class="fa fa-check"></i><b>3.2.1</b> Lecture 1 :전자의무기록에 기반한 임상 빅데이터 연구 Alexander Turchin (Harvard University, Brigham and Women’s Hospital, USA)</a></li>
<li class="chapter" data-level="3.2.2" data-path="parallel-session-i-chairperson-.html"><a href="parallel-session-i-chairperson-.html#lecture-2----tom-lawry-microsoft-corp.-usa"><i class="fa fa-check"></i><b>3.2.2</b> Lecture 2 : 의료분야에서의 빅데이터 분석 Tom Lawry (Microsoft Corp., USA)</a></li>
<li class="chapter" data-level="3.2.3" data-path="parallel-session-i-chairperson-.html"><a href="parallel-session-i-chairperson-.html#lecture-3-------"><i class="fa fa-check"></i><b>3.2.3</b> Lecture 3 :생물기작 기반 암 오믹스 데이터 분석 기법</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="4" data-path="acrep.html"><a href="acrep.html"><i class="fa fa-check"></i><b>4</b> ACREP</a><ul>
<li class="chapter" data-level="4.1" data-path="observational-study.html"><a href="observational-study.html"><i class="fa fa-check"></i><b>4.1</b> Observational Study</a><ul>
<li class="chapter" data-level="4.1.1" data-path="observational-study.html"><a href="observational-study.html#contents"><i class="fa fa-check"></i><b>4.1.1</b> Contents</a></li>
</ul></li>
<li class="chapter" data-level="4.2" data-path="observational-study-pitfall-.html"><a href="observational-study-pitfall-.html"><i class="fa fa-check"></i><b>4.2</b> Observational Study의 Pitfall 및 이를 극복하기 위한 방법</a><ul>
<li class="chapter" data-level="4.2.1" data-path="observational-study-pitfall-.html"><a href="observational-study-pitfall-.html#experimental-study-yes"><i class="fa fa-check"></i><b>4.2.1</b> Experimental study? Yes</a></li>
<li class="chapter" data-level="4.2.2" data-path="observational-study-pitfall-.html"><a href="observational-study-pitfall-.html#experimental-study-no"><i class="fa fa-check"></i><b>4.2.2</b> Experimental study? No</a></li>
<li class="chapter" data-level="4.2.3" data-path="observational-study-pitfall-.html"><a href="observational-study-pitfall-.html#contents-1"><i class="fa fa-check"></i><b>4.2.3</b> Contents</a></li>
<li class="chapter" data-level="4.2.4" data-path="observational-study-pitfall-.html"><a href="observational-study-pitfall-.html#conclusion"><i class="fa fa-check"></i><b>4.2.4</b> Conclusion</a></li>
</ul></li>
<li class="chapter" data-level="4.3" data-path="diagnostic-test-biomarker-study.html"><a href="diagnostic-test-biomarker-study.html"><i class="fa fa-check"></i><b>4.3</b> Diagnostic test &amp; Biomarker Study</a><ul>
<li class="chapter" data-level="4.3.1" data-path="diagnostic-test-biomarker-study.html"><a href="diagnostic-test-biomarker-study.html#contents---diagnostic-test"><i class="fa fa-check"></i><b>4.3.1</b> Contents - Diagnostic test</a></li>
<li class="chapter" data-level="4.3.2" data-path="diagnostic-test-biomarker-study.html"><a href="diagnostic-test-biomarker-study.html#contents---biomarker"><i class="fa fa-check"></i><b>4.3.2</b> Contents - Biomarker</a></li>
</ul></li>
<li class="chapter" data-level="4.4" data-path="-.html"><a href="-.html"><i class="fa fa-check"></i><b>4.4</b> 2차 자료원을 이용한 역학 연구군</a></li>
<li class="chapter" data-level="4.5" data-path="-clinical-prediction-model-individual-riskoutcome-probability-.html"><a href="-clinical-prediction-model-individual-riskoutcome-probability-.html"><i class="fa fa-check"></i><b>4.5</b> 대규모 이차 자료원을 이용한 clinical prediction model : individual risk/outcome probability 예측 분석법</a></li>
<li class="chapter" data-level="4.6" data-path="web-r-org.html"><a href="web-r-org.html"><i class="fa fa-check"></i><b>4.6</b> Web-r.org</a><ul>
<li class="chapter" data-level="4.6.1" data-path="web-r-org.html"><a href="web-r-org.html#contents-2"><i class="fa fa-check"></i><b>4.6.1</b> Contents</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="5" data-path="prism.html"><a href="prism.html"><i class="fa fa-check"></i><b>5</b> Prism</a><ul>
<li class="chapter" data-level="5.1" data-path="morning.html"><a href="morning.html"><i class="fa fa-check"></i><b>5.1</b> Morning</a><ul>
<li class="chapter" data-level="5.1.1" data-path="morning.html"><a href="morning.html#lim-covariate-model"><i class="fa fa-check"></i><b>5.1.1</b> Lim Covariate model</a></li>
<li class="chapter" data-level="5.1.2" data-path="morning.html"><a href="morning.html#fda---lee"><i class="fa fa-check"></i><b>5.1.2</b> FDA - Lee</a></li>
<li class="chapter" data-level="5.1.3" data-path="morning.html"><a href="morning.html#pfizer"><i class="fa fa-check"></i><b>5.1.3</b> Pfizer</a></li>
</ul></li>
<li class="chapter" data-level="5.2" data-path="prism-afternoon.html"><a href="prism-afternoon.html"><i class="fa fa-check"></i><b>5.2</b> PRISM Afternoon</a><ul>
<li class="chapter" data-level="5.2.1" data-path="prism-afternoon.html"><a href="prism-afternoon.html#kim"><i class="fa fa-check"></i><b>5.2.1</b> Kim</a></li>
<li class="chapter" data-level="5.2.2" data-path="prism-afternoon.html"><a href="prism-afternoon.html#strategic-application-of-pm-in-global-drug-development-experience-from-hanmi"><i class="fa fa-check"></i><b>5.2.2</b> Strategic application of PM in global drug development: Experience from Hanmi</a></li>
<li class="chapter" data-level="5.2.3" data-path="prism-afternoon.html"><a href="prism-afternoon.html#mbdd"><i class="fa fa-check"></i><b>5.2.3</b> MBDD</a></li>
<li class="chapter" data-level="5.2.4" data-path="prism-afternoon.html"><a href="prism-afternoon.html#pharmacometric-information-in-drug-label"><i class="fa fa-check"></i><b>5.2.4</b> Pharmacometric information in drug label</a></li>
<li class="chapter" data-level="5.2.5" data-path="prism-afternoon.html"><a href="prism-afternoon.html#pharmacometrics-in-dose-optimization"><i class="fa fa-check"></i><b>5.2.5</b> Pharmacometrics in Dose Optimization</a></li>
</ul></li>
</ul></li>
<li class="chapter" data-level="6" data-path="mfds-asan-joint-symposium-on-rare-diseases-2016.html"><a href="mfds-asan-joint-symposium-on-rare-diseases-2016.html"><i class="fa fa-check"></i><b>6</b> MFDS-Asan Joint Symposium on Rare Diseases 2016</a><ul>
<li class="chapter" data-level="6.1" data-path="session-1-rare-diseases-in-korea-status-research-experiences.html"><a href="session-1-rare-diseases-in-korea-status-research-experiences.html"><i class="fa fa-check"></i><b>6.1</b> Session 1 Rare diseases in Korea : Status &amp; Research experiences</a><ul>
<li class="chapter" data-level="6.1.1" data-path="session-1-rare-diseases-in-korea-status-research-experiences.html"><a href="session-1-rare-diseases-in-korea-status-research-experiences.html#national-support-for-rare-disease-current-status-and-future-prospects"><i class="fa fa-check"></i><b>6.1.1</b> National support for rare disease : Current status and future prospects</a></li>
<li class="chapter" data-level="6.1.2" data-path="session-1-rare-diseases-in-korea-status-research-experiences.html"><a href="session-1-rare-diseases-in-korea-status-research-experiences.html#translational-research-for-drug-development-historical-perspective"><i class="fa fa-check"></i><b>6.1.2</b> Translational research for drug development : Historical perspective</a></li>
</ul></li>
<li class="chapter" data-level="6.2" data-path="session-2-global-regulatory-experiences-in-orphan-drug-development.html"><a href="session-2-global-regulatory-experiences-in-orphan-drug-development.html"><i class="fa fa-check"></i><b>6.2</b> Session 2 Global regulatory experiences in orphan drug development</a><ul>
<li class="chapter" data-level="6.2.1" data-path="session-2-global-regulatory-experiences-in-orphan-drug-development.html"><a href="session-2-global-regulatory-experiences-in-orphan-drug-development.html#considerations-for-drug-development-for-rare-diseases"><i class="fa fa-check"></i><b>6.2.1</b> Considerations for drug development for rare diseases :</a></li>
</ul></li>
<li class="chapter" data-level="6.3" data-path="session-3-lessons-and-learned-rd-for-rare-disease.html"><a href="session-3-lessons-and-learned-rd-for-rare-disease.html"><i class="fa fa-check"></i><b>6.3</b> Session 3 Lessons and learned : R&amp;D for rare disease</a></li>
<li class="chapter" data-level="6.4" data-path="session-4-asan-initia-tives-for-rare-disease.html"><a href="session-4-asan-initia-tives-for-rare-disease.html"><i class="fa fa-check"></i><b>6.4</b> Session 4 Asan initia tives for rare disease</a></li>
</ul></li>
<li class="divider"></li>
<li><a href="http://shanmdphd.github.io">Back to shanmdphd.github.io</a></li>

</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">Conferences 2016</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="observational-study-pitfall-----" class="section level2">
<h2><span class="header-section-number">4.2</span> Observational Study의 Pitfall 및 이를 극복하기 위한 방법</h2>
<ul>
<li>Speaker: 임영석 교수님</li>
</ul>
<div id="experimental-study-yes" class="section level3">
<h3><span class="header-section-number">4.2.1</span> Experimental study? Yes</h3>
<div id="randomized-design-interventional--no" class="section level4">
<h4><span class="header-section-number">4.2.1.1</span> Randomized design? (interventional)- No</h4>
<ul>
<li>NR CLINICAL trial</li>
<li>Time series</li>
<li>PHASE 1</li>
</ul>
</div>
<div id="randomized-design-interventional--yes" class="section level4">
<h4><span class="header-section-number">4.2.1.2</span> Randomized design? (interventional)- Yes</h4>
<ul>
<li>Clinical Trial</li>
<li>Community Trial</li>
<li>Crossover design</li>
</ul>
</div>
</div>
<div id="experimental-study-no" class="section level3">
<h3><span class="header-section-number">4.2.2</span> Experimental study? No</h3>
<div id="comparison-group-no-observational-study" class="section level4">
<h4><span class="header-section-number">4.2.2.1</span> Comparison group? No = Observational study</h4>
<ul>
<li>Prevalence / incidence,</li>
<li>time trend,</li>
<li>case series,</li>
<li>case reoprt</li>
</ul>
</div>
<div id="comparison-group-yes-analytical-study" class="section level4">
<h4><span class="header-section-number">4.2.2.2</span> Comparison group? Yes = Analytical study</h4>
<ul>
<li>Cohort study,</li>
<li>case-control study,</li>
<li>cross-sectional study,</li>
<li>ecologic study,</li>
<li>PMS</li>
<li>두군을 비교하는가 안하는가가 중요한 기준이 된다.</li>
</ul>
</div>
</div>
<div id="contents-1" class="section level3">
<h3><span class="header-section-number">4.2.3</span> Contents</h3>
<ul>
<li>research question -(design)- study plan -(implement)- actual study</li>
<li>findings in the study -(infer)- truth in the study -(infer)- truth in the universe</li>
<li>위암, 대장, 폐암 - post op outcome을 통채로 비교하면 안된다.</li>
<li>internal validity &amp; external validity(generalization)</li>
<li>PICO anatomy #####</li>
<li>patient/population/problemn</li>
<li>Intervention</li>
<li>Comparison</li>
<li>Outcome</li>
<li>Gold standard of clinical studies - RCT</li>
<li>Sample - randomization (Treated / Control)</li>
<li>Research question - interesting, important, critical</li>
<li>Good research question - FINER - Feasible, Interesting, Novel, Ethical, Relevant</li>
<li>Feasible / Ethical / Relevant 가장 중요한 면</li>
<li>Prospective Cohort Study -</li>
<li>Case-control study - 뒤로 간다. 병원에서 case-control 하는 경우는 사망여부. Outcome인 경우가 많다. disease있고 없고가 아니라.</li>
<li>재발에 대한 - 환자군/대조군을 모아서. 그럼 어떻게 대조군 설정한건가?? 이런 것을 정할때 bias가 많이 발생하게 된다.</li>
<li>Historical cohort - Cohort assembled-(f/u)-&gt;Outcome</li>
<li>2000-2010 HCC 초치료 근치적 수술적 절제술 받은 환자들의 명단을 확보.</li>
<li>ITT analysis할때 반드시 필요하다.</li>
<li>5년 이상 관찰한 것이 있어.</li>
<li>Mimic those of clinical trials</li>
<li>Internal validity를 높여야 한다. restricted cohort / NEJM 2000;342:1887</li>
<li>IIT 분석을 해라.</li>
<li>Chance(Random Error) vs Bias(Systematic Error)</li>
<li>association / cause를 비교해야.</li>
<li>Confounder</li>
<li>biasd와는 좀 다르다. 미리 의식하고 물어보기 전엔 절대 알수 없다. 미리 질환에 대해 잘 알고있는 연구자여야만 찾을 수 있다.</li>
<li>Example : smoking - alcohol - heart disease</li>
<li>What is the effect of long-term tx(&gt;5y) with a potent oral antiviral agent(entecavir)(I) in patients with chronic hep B(P)</li>
<li>FDA, 식약처는 Surrogate marker를 가지고 허가를 내준다. (조직학적 개선,) - 이것과 환자의 outcome을 정말로 개선시키는건가? 이건 observational study에서만 찾을 수 있다. historical cohort</li>
<li>Zero time No treatment control</li>
<li>Endpoint ascertainment - 재발이 문제가 된다. 무엇으로 재발을 판정할 것인가? MR? CT? 검사간격을 얼마로 했니? 누구도 시비 못할 것으로 outcome measure하는 것이 좋다. (예를 들어 사망의 경우)</li>
<li>PP vs ITT</li>
<li>ITT - which treatment option is best at the time decision must be made? - FDA에서 ITT만 인정을 한다.</li>
<li>Explanatory</li>
<li>Multivariable Cox PH Analysis - (Event 수를 적어야 한다.) Univariate analysis만으로는 부족.</li>
<li>Multivariate analysis -</li>
<li>Propensity score - SPSS로 가능. 양군간 matching - 쌍을 갖춘다. 같은 수로 나온다. 이때는 univariate할 수 있다.</li>
<li>“consistently observed by unadjusted.” - obs study는 의심을 많이 받기 때문에. 이런 분석을 하는 것이 좋다.</li>
<li>Gadoxetic - liver specific contrast agent</li>
<li>2647patients-&gt;700명 수술 가능. - surrogate marker - CT에서 못본걸 MR에서 찾았다. | Cost-effectiveness - 무조건 survival. Propensity matching - Inverse Probability Weighing (IPTW)
<ol style="list-style-type: decimal">
<li>Unadjsted</li>
<li>mutivariable</li>
<li>IPTW</li>
<li>Propensity</li>
</ol></li>
<li>제목의 중요성. JCO (IF 21) - Hepatology (IF 11.7) - Gut (IF 14.921) (early rejection so far) - GE (IF 18.187) (accepted with more general terms in the title)</li>
</ul>
</div>
<div id="conclusion" class="section level3">
<h3><span class="header-section-number">4.2.4</span> Conclusion</h3>
<ul>
<li>mimic as closely as possible in RCT</li>
</ul>
</div>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="observational-study.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="diagnostic-test-biomarker-study.html" class="navigation navigation-next " aria-label="Next page""><i class="fa fa-angle-right"></i></a>

<script src="libs/gitbook/js/app.min.js"></script>
<script src="libs/gitbook/js/lunr.js"></script>
<script src="libs/gitbook/js/plugin-search.js"></script>
<script src="libs/gitbook/js/plugin-sharing.js"></script>
<script src="libs/gitbook/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook/js/plugin-bookdown.js"></script>
<script src="libs/gitbook/js/jquery.highlight.js"></script>
<script>
require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"facebook": true,
"twitter": true,
"google": false,
"weibo": false,
"instapper": false,
"vk": false,
"all": ["facebook", "google", "twitter", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": "https://github.com/shanmdphd/shanmdphd.github.io/edit/master/_ConferencesSource/2016-06-24-ACREP.rmd",
"text": "Edit"
},
"download": ["bookdown.pdf", "bookdown.epub", "bookdown.mobi"],
"toc": {
"collapse": "subsection"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://cdn.mathjax.org/mathjax/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    if (location.protocol !== "file:" && /^https?:/.test(script.src))
      script.src  = script.src.replace(/^https?:/, '');
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
